Teva rasagiline submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva submits rasagiline NDA Aug. 8 for treatment of Parkinson's disease (PD). Rasagiline differs from other MAO-B inhibitors "in its chemical structure, its greater potency, lack of amphetamine metabolites and once-a-day dosing," the firm says. Somerset's Eldepryl (selegiline), the only approved PD drug in the MAO-B class, is administered twice daily. Teva will likely stress efficacy in the "off" period when PD symptoms are not adequately controlled. In the 18-week LARGO trial, rasagiline added to levodopa reduced "off" time by 1.2 hours daily or 21%. Rasagiline also significantly improved motor function based on the Unified PD Rating Scale in "on" and "off" states, while the comparator, Novartis' Comtan (entacapone), similarly improved scores in the "on" state but did not impact scores in the "off" state. Teva recently signed a co-promotion deal with Eisai; the firms are also developing the agent for Alzheimer's disease (1Pharmaceutical Approvals Monthly June 1, 2003, In Brief)...
You may also be interested in...
Teva Agilect "approvable"
Teva/Eisai's Parkinson's therapy Agilect (rasagiline) is "approvable" at FDA, the firm announces July 5. The NDA, submitted August 8, 2003, covers use of the MAO-B inhibitor as monotherapy in early Parkinson's disease and as adjunct therapy to levodopa in moderate-to-advanced stages of PD. Teva is highlighting once-daily dosing (1Pharmaceutical Approvals Monthly Sept. 1, 2003, In Brief)...
Teva/Eisai rasagiline deal
Eisai will co-promote Teva's MAO-B inhibitor rasagiline in North America for Parkinson's disease under a deal that also calls for global co-development for Alzheimer's disease. Teva recently announced successful completion of its Phase III Parkinson's program, with an FDA filing set for second half 2003 (1Pharmaceutical Approvals Monthly May 1, p. 14)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.